ReviewExploration (Beijing, China)2025
Tau-targeting nanoparticles for treatment of Alzheimer's disease.
Review in Exploration (Beijing, China), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- When copper turns killer: Decoding copper dyshomeostasis and cuproptosis in neurodegenerative pathogenesis and precision metal interventions.Neural regeneration research · 2026Article
- Development of a Novel AAV-Mediated microRNA Gene Therapy for Spatial Suppression of BACE1 to Improve Cognitive Function in Alzheimer's Disease Model Mice.Biomolecules · 2026Article
- Targeted nanomedicine strategies for Alzheimer's disease therapy.Discover nano · 2026Review
- Article
- Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions.International journal of molecular sciences · 2026Review
- Plasma-Nanomedicine Synergistic Therapy for Brain Diseases: Current Status, Applications, and Challenges.Antioxidants (Basel, Switzerland) · 2026Review
- Overcoming the blood-brain barrier in Alzheimer's disease: translational perspectives on advanced drug delivery platforms.Frontiers in neuroscience · 2026Review
- Research Progress of Lipid Metabolism-Mediated Neuroinflammation in Alzheimer's Disease.Cellular and molecular neurobiology · 2025Review
- Advances in Lipid-Polymer Hybrid Nanoparticles: Design Strategies, Functionalization, Oncological and Non-Oncological Clinical Prospects.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Integrating artificial intelligence with nanodiagnostics for early detection and precision management of neurodegenerative diseases.Journal of nanobiotechnology · 2025Review
- The potential of plant-derived vesicles in treating periodontitis and associated systemic diseases: current advances and future directions.Journal of nanobiotechnology · 2025Review
- Ceria-nanocluster based therapy for Alzheimer's disease through the modulation of activated microglia and attenuation of amyloid-β deposition.Cell biomaterials · 2025Article
- Exploring the Neuroprotective Role of Selenium: Implications and Perspectives for Central Nervous System Disorders.Exploration (Beijing, China) · 2025Review
- Bioactive compound nanoparticles for Alzheimer's disease.Inflammopharmacology · 2025Review
- Tau-targeting nanoparticles for treatment of Alzheimer's disease.Exploration (Beijing, China) · 2025Review
- Alzheimer's disease recognition via long-range state space model using multi-modal brain images.Frontiers in neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the loss of neural connections and decreased brain tissue volume. Initially affecting the hippocampus and entorhinal complex, which are responsible for memory, the disease later impacts the cerebral cortex, controlling language, logic, and social conduct. While the exact cause is unknown, genetic mutations and environmental factors are implicated. Diagnosis involves computed tomography (CT) scans, Magnetic resonance imaging (MRIs), Positron emission tomography (PET) scans, and lumbar punctures to detect brain abnormalities, protein deposits, and cerebrospinal fluid biomarkers. AD features beta-amyloid plaques and neurofibrillary tau tangles that disrupt neuronal function, chronic inflammation, blood-brain barrier impairment, brain atrophy, and neuronal death. There is no cure; current treatments manage symptoms and slow cognitive decline. Research into genetic, cellular, and molecular pathways aims to develop targeted therapies. Tau tangle accumulation is closely linked to AD, making it crucial to explore therapies that restore normal tau pathways and prevent tau accumulation. Nanoparticulate drug delivery technologies offer promise in this area. This review discusses the potential of nanotechnology-based therapies to target AD-related tau accumulation and restore normal tau protein mechanics, which could preserve neuronal transmission, synaptic integrity, and brain tissue volume.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.